Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation.
Droxicam, similar to piroxicam, inhibits in vivo renal synthesis of PGF2 alpha. This study was performed in rats; droxicam and piroxicam were administered orally at doses of 0.5, 1.2 and 8 mg/kg. Inhibitory activity of the two compounds was similar (40-60%) but showed no dose-effect relationship. Maximum inhibition was obtained with the 1 mg/kg dosage. In dogs droxicam has shown a clear inhibitory effect on arachidonic acid induced ex vivo platelet aggregation. Droxicam was administered orally at a dose of 2 mg/kg. Maximum inhibition (-40%) was achieved 24 hr post-administration and the effect was sustained up to 72 hr (-23%).
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000652:urine; D015237:Dinoprost; D004285:Dogs; D007668:Kidney / Q000378:metabolism; D008297:Male; D010894:Piroxicam / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011448:Prostaglandin Antagonists; D011460:Prostaglandins F / Q000096:biosynthesis* / Q000652:urine; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001095:Arachidonic Acids; D011448:Prostaglandin Antagonists; D011460:Prostaglandins F; D011725:Pyridines; D010894:Piroxicam; D016718:Arachidonic Acid; D015237:Dinoprost; C049073:droxicam